FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.
What happened
FDA inspected the drug manufacturing facility in Canoga Park, CA, from June 16 to 23, 2025. It found the company lacked an adequate quality control unit and continued distributing batches of over-the-counter (OTC) drugs after its contract manufacturer reported elevated impurities; the company later recalled some batches. FDA also found no drug listings for at least 21 human OTC drugs.
What FDA found
The company did not have an adequate quality control unit with the authority to approve or reject materials and products and to review production records.
21 CFR 211.22(a)The company continued to distribute OTC drug batches after its contract manufacturer told it the batches had elevated impurities.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)The company did not list at least 21 human OTC drugs with FDA as required.
FD&C Act section 510(j), 21 U.S.C. 360(j); 21 CFR Part 207The company's written response did not assess the impact on other batches and other products containing the same ingredient that had been released and were still on the market.
21 CFR 211.22(a)As the product owner using a contract manufacturer, the company did not ensure its quality unit approved or rejected the contractor's products and services, including batch release.
21 CFR 211.22(a)
What FDA wants
FDA tells the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence. The response should include a quality-unit remediation plan and test results for retained samples of affected products still on the U.S. market.
Who should pay attention
- brands that rely on contract manufacturers for OTC drugs
- owners and labelers of OTC drug products
- contract manufacturers and distributors of OTC skin-care drugs
This is a summary. Read the original letter on fda.gov.